Company intelligence / Profile preview

Diakonos Oncology

Houston, Texas, United Statesdiakonosoncology.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Phase 1 trial for GBM showed 88% 12-month survival rate compared to 53% historical survival with standard of care. 12 of 16 newly diagnosed GBM patients remained alive with no serious adverse events attributable to DOC1021 at an average of 12.9 months follow-up. The company has received Fast Track and Orphan Drug designations from the FDA for GBM and Fast Track designation for pancreatic cancer.[10][9]

Therapeutic areas: Oncology
Modalities: Dendritic Cell Vaccines (DCVs)
Industry: Biotech

Drug pipeline

4 assets

autologous dendritic cell vaccine

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Diakonos Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diakonos Oncology.

Explore the full profile